The Maudsley Deprescribing Guidelines is the most important psychiatric book of the last decade - not because it's perfect, but because it exists. For the first time, a mainstream clinical publisher under one of the most respected names in psychopharmacology says: withdrawal is real, it can be devastating, and drugs should be tapered gradually, with smaller reductions at lower doses.
The core principle is correct and life-changing. The execution has problems. The tapering tables are built around convenient pill fractions rather than consistent percentage reductions, and violate their own stated receptor occupancy limits. All benzodiazepine curves are derived from a 1991 monkey study extrapolated via equivalency tables. The book relies on 37 "in preparation" self-citations - key papers that remain unpublished over two years later. Critical topics are completely absent or barely addressed: MCAS/mast cell activation, meaningful supplement guidance, and the CBD evidence base. The book's only practical dosing advice involves cutting pills - no milligram scales, no proper mathematical tools, no jump dose guidance.
My verdict: Read it for the principles. Don't follow the tables blindly. Use a proper percentage-based calculation tool and a milligram scale. And if you're a clinician - please listen to your patients. They know their bodies.
A personal note: It frustrates me deeply that anything better than "just cut your dose in half and then stop" is considered a breakthrough. The bar is on the floor. If a cardiology textbook cited monkey studies as the basis for dosing guidance, relied on 37 unpublished self-references, and came with a disclaimer saying "this advice is not necessarily correct" - it would never have been published. But because these are psychiatric patients, it's celebrated. People on psychiatric drugs are treated like medicine's forgotten underclass - the ones outside the walls, who can be mistreated with minimal consequence because they're already stigmatised. Every other field of medicine demands better evidence, better precision, better accountability. Why don't we?
I originally published this review as a YouTube video where I went through the book section by section. Since then, I've done significantly more research - including tracing every major reference back to its source, re-reading sections I flagged, and cross-checking my claims against the actual text with much more precision. This written version corrects a couple of errors from my original video (details below), adds substantial new analysis not covered in the video, and provides a more balanced assessment overall.
Key corrections: I was wrong that agomelatine was only mentioned once - it has a full dedicated section. I now acknowledge the term "hyperbolic" is technically correct for the dose-response curve, even though I still believe "exponential decay taper" or "percentage-based taper" is clearer for patients. The key "in preparation" papers the book relies on (particularly the benzodiazepine paper) are still unpublished as of March 2026 - over two years after the book came out. This written version also includes extensive new sections on topics not covered in the original video - including CYP enzyme metabolism, MCAS, excipient sensitivities, emergency protocols, and other gaps I've identified through deeper analysis. These are clearly marked as additional findings throughout.
I am not a doctor. My knowledge comes from thorough personal research, extensive lived experience with benzodiazepine withdrawal, the lived experience of hundreds of people I've helped or worked alongside, a Peer Mental Health Support Certificate IV, and a lifetime spent close to psychiatry through my mother - a former child and adolescent psychiatrist who herself went through severe chronic illness. This is not medical advice. Always work with an informed clinician. I used AI tools to assist in parts of this research, but independently verified every claim. Everything stated here is my honest opinion based on what I found.
The Maudsley Deprescribing Guidelines is a 587-page clinical handbook written by Mark Horowitz and David Taylor, published by Wiley in February 2024. Horowitz is a trainee psychiatrist and Clinical Research Fellow at North East London NHS Trust who runs a deprescribing clinic; Taylor is Director of Pharmacy and Pathology at the South London and Maudsley NHS Trust and Professor of Psychopharmacology at King's College London. Both have personal experience of stopping psychiatric drugs.
The book builds on the reputation of the Maudsley Prescribing Guidelines - a cornerstone of psychiatric practice with over 300,000 copies sold across 14 editions. It provides step-by-step tapering guidance for antidepressants, benzodiazepines, gabapentinoids and z-drugs, with fast, moderate and slow schedules for each commonly prescribed medication.
I first encountered Horowitz's work through his Zoom lecture with Benzo Warriors in mid-2023, while I was in severe withdrawal myself. That lecture covers much of the same material as the book - receptor occupancy, the hyperbolic principle, the comparison with exponential tapering - and in many ways can serve as a condensed introduction to the book's core argument. If you can't access the book, that lecture is worth watching.
The book is structured into four main sections: an introductory overview of deprescribing principles, then dedicated chapters on antidepressants, benzodiazepines/z-drugs, and gabapentinoids. Each drug gets its own sub-section with pharmacological information, deprescribing notes, and detailed tapering tables showing dose steps alongside estimated receptor occupancy percentages. One structural note: there is significant repetition between chapters - the general principles from Chapter 1 are restated in each drug-class chapter. The authors acknowledge this is deliberate, so that each chapter can stand alone as a reference. It makes the book longer but means you don't have to read it cover to cover.
The book explicitly states on page 15 that its advice is based on "a combination of literature review, clinical experience and expert contribution, including from patient experts and advocates." The information is current to November 2023.
The central argument of this book is correct and profoundly important: psychiatric drugs should be tapered gradually, and the rate of tapering needs to slow down as the dose gets lower. This is because the relationship between dose and effect on receptors is not linear - it follows a hyperbolic curve described by the law of mass action (or Michaelis-Menten kinetics). A reduction from 20mg to 10mg of an SSRI is a much smaller change in receptor occupancy than a reduction from 10mg to zero.
This principle alone makes the book revolutionary in the context of mainstream psychiatric practice. For decades, clinical guidelines recommended rapid tapers over two to four weeks - advice that caused immense suffering. The Maudsley Deprescribing Guidelines explicitly rejects this approach and provides an evidence-based framework for why gradual reduction is essential.
Each commonly prescribed antidepressant, benzodiazepine, gabapentinoid and z-drug gets its own dedicated section with specific tables. The book provides three taper speeds - fast, moderate and slow - allowing clinicians to tailor the approach to individual patients.
The book takes withdrawal seriously. It acknowledges protracted withdrawal syndrome, discusses the problem of withdrawal symptoms being mistaken for relapse, and was developed with input from patient experts. This represents a significant shift from the historical dismissal of withdrawal concerns by the psychiatric establishment.
The book discusses several methods for achieving small doses: liquid formulations, tablet splitting, compounding pharmacies, and bead counting for capsule medications. For duloxetine, it even mentions using a jeweller's scale to weigh beads (page 155), showing awareness that precise dosing matters at small amounts.
One thing the book does well is include metabolic notes for several antidepressants. For paroxetine (page 274) it discusses P450 2D6 inhibition and what happens as doses are reduced. For fluvoxamine (page 243) it addresses CYP P450 1A2 effects. The fluoxetine section (page 118) discusses both P450 2D6 metabolism and norfluoxetine's role (its active metabolite with a 7–15 day half-life). These are genuinely useful clinical details - though as I discuss in Section 06, there’s a significant gap when it comes to CYP2C19 and diazepam.
One correction up front: the book does describe water-based suspensions and also mentions full-fat milk as an alternative medium for some benzodiazepines. It gives a concrete worked example (for estazolam) showing how to crush a tablet, disperse it into a measured volume to create a suspension (e.g., 0.1mg/mL), shake vigorously, and then draw up the target volume with a syringe. It also warns that stability can’t be assumed and advises consuming immediately and discarding any unused mixture.
That said, the guidance remains “just enough to say it exists” rather than the kind of practical, failure-proof instruction that real patients in withdrawal need. The book never really grapples with the messiest reality: most dispersions are suspensions, not solutions; particles can settle quickly; brands differ; and tiny measurement errors become huge relative errors at low doses. It tells you to shake vigorously — but doesn’t give the “how-to” detail (timing, syringe size, technique, repeatability checks) that makes the method reliable in the real world.
This is the part that still makes me angry — because I see people get hurt by it in real time.
In the book, “micro‑tapering” is presented as a way to make smaller reductions by spreading a reduction across time: daily cuts rather than cut‑and‑hold. It even describes how to derive a daily rate by dividing a step change across a time window (e.g., taking a reduction and spreading it over 14–28 days), and it also says clinicians can insert intermediate “halfway” steps between the listed doses for a more gradual taper. But the book does not give a concrete, patient‑proof method for turning that idea into actual day‑by‑day doses when you’re still working with tablets and real‑world formulations. The result is that people hear “microtaper” and think “gentle by definition,” when in practice it can become either (a) a hidden linear taper, or (b) a daily taper that’s impossible to troubleshoot because you never know which day’s cut caused the crash.
What I keep seeing in the wild is people doing a “microtaper” that is really just a linear liquid taper: put a pill in, say, 300mL of water and remove 1mL more each day. That is a linear taper (a fixed amount off the original dose). Linear tapers accelerate as you get lower: at the start it may be ~10% per month, but around the halfway point you’re effectively going ~20% per month, and near the end you can be forcing ~25–35% reductions over a month. People then interpret the worsening symptoms as “this is just the end game,” when in reality they unknowingly sped up the taper.
There’s a second trap: even if you do a mathematically correct daily taper (tiny percentage cuts from the current dose), you may not feel the effects immediately — especially with longer‑acting benzodiazepines. If you reduce every day, you can keep cutting for a week while your nervous system is only starting to register what you did. When symptoms finally spike, troubleshooting becomes guesswork: was it day 2? day 6? the flu you caught? a brand change? You can’t know.
And then there’s the practical chemistry: most benzodiazepine tablets don’t actually dissolve in water — they suspend. Unless you are using a validated method (proper mixing, consistent technique, appropriate suspension medium), liquid “microtapers” can become inaccurate or inconsistent. Milk suspensions can help for some drugs because fat can dissolve lipophilic compounds, but that still requires careful technique and is not universally applicable.
If you want a repeatable “micro” approach without relying on shaky liquid math or brand-dependent suspensions, I recommend a dry cut using a jeweller’s scale and powdered tablets — and then apply an exponential / %‑of‑current‑dose taper schedule (with holds long enough to see how your body actually responds).
Here’s my step‑by‑step video showing how to do dry cuts with a scale (and how I use my free GTT taper calculator/software to generate the daily targets): https://www.youtube.com/watch?v=NdP2nKanAVE
The antidepressant bead method is a good example of the book’s overall pattern: it acknowledges the problem, then moves on before drawing out the practical consequence. The text notes that bead counts can vary because beads vary in size, and even suggests estimating an average across multiple capsules. It even concedes that weighing beads with a jeweller’s scale “may allow greater accuracy”. But it doesn’t clearly spell out what patients and clinicians need to hear: bead counting is not inherently “precise” unless the beads are uniform, and uniformity varies by brand and even by batch. In practice, that means your “5%” can silently become “something else” unless you verify and standardise the method.
In my own tapering world, the milligram jeweller’s scale is the default tool for almost any tablet-based taper because it gives you a universal way to do consistent percentage reductions without relying on tidy halves and quarters. This matters even more in places like Australia where tablet options can be limited, and where two strengths may weigh the same (meaning you can’t safely infer dose from tablet mass without doing the calculation properly). This is exactly where a “tables-first” approach breaks: reality is ugly numbers, not neat fractions.
A final point that isn’t “scientific” but is absolutely clinical: this book is often read by people in withdrawal, with cognitive load already crushed. In my Kindle edition, some tables were difficult to view and navigate, especially on certain devices and layouts. If the tables are the “practical” core of the book, they have to be easy to read in the formats people actually buy.
This is the single most important practical criticism of this book. The tapering tables are structured around what can be achieved by cutting tablets into halves and quarters, not around consistent percentage reductions. The method columns literally read "Use tablets," "Use ½ tablets," "Use ¼ tablets."
The problem is that cutting a tablet in half is not a 50% reduction in receptor occupancy - it's a 50% reduction in dose, which at lower doses translates to a disproportionately large change in receptor effect. The whole point of the book's own argument is that equal dose reductions cause increasingly large changes in receptor occupancy at lower doses. Yet the tables systematically violate this principle by relying on convenient pill fractions.
I went through the tables with a calculator. Take the clonazepam moderate taper, which states it produces reductions of "up to 2.5 percentage points" in receptor occupancy. Step 8 to Step 9 is actually 2.8 percentage points. That exceeds the book's own stated maximum. In the fast taper tables, the inconsistencies are even larger. The RO% jumps in the diazepam fast table (stated as "up to 5 percentage points") bounce around from 1.8 to 4.6 across different steps - they're all over the place rather than being the even, predictable reductions the methodology demands.
For a book that positions itself as applying precise pharmacological science to tapering, the tables don't follow their own rules. Patients and clinicians trusting these numbers as mathematically derived will be misled about the actual magnitude of changes at each step.
The word "jeweller's" appears exactly once in this 587-page book - in the antidepressant section for weighing duloxetine beads (page 155). It never appears in the benzodiazepine chapter at all.
This is a critical gap. A milligram-precision jeweller's scale (costing around $20–30) is arguably the single most practical tool for achieving consistent percentage-based reductions for any tablet medication. You weigh the tablet, calculate the target weight after a 10% reduction, and shave or crush to that weight. It works for any drug, doesn't require expensive compounding, and actually achieves the mathematical consistency the book advocates. Its near-total omission is baffling.
A proper exponential decay taper is simple: reduce by a fixed percentage of your current dose each step - the well-known "10% rule" recommended by NICE in the UK and widely used in the withdrawal community. If you're reducing by 10%, you multiply your current dose by 0.9 each time. This naturally produces smaller and smaller absolute reductions as the dose gets lower - exactly what the science demands. You don't need receptor occupancy curves or EC50 values to implement this. You need a calculator and a jeweller's scale. This is the approach my own tapering tool uses - adjustable, precise percentage-based exponential decay where you control the rate and can slow down or speed up based on how you're feeling. The maths is simple and the results are more consistent than following rounded tables.
The receptor occupancy curves that underpin the antidepressant tapering tables come primarily from Horowitz's own 2019 Lancet Psychiatry paper, which uses PET imaging data to model the relationship between dose and serotonin transporter (SERT) occupancy. That paper draws on studies like Meyer 2004, and the data was later synthesised in Sørensen et al.'s systematic review in Molecular Psychiatry (published online in 2021; print 2022) (17 studies, 294 participants, 10 drugs).
The limitations of this data are significant and, to the book's credit, occasionally acknowledged:
Six of the 17 studies used only a single dose. Most participants were healthy volunteers aged 25–40, predominantly male. The longest study duration was approximately two months. Not a single study examined people who had been on these medications for years - the very population the book is designed to help. Sørensen's own paper acknowledges this, stating that occupancy data from single-dose studies "may underestimate the occupancy occurring in patients who take the drugs continuously for extended periods."
So the EC50 values driving these curves may not accurately reflect what's happening in the brains of long-term users. The principle of hyperbolic dose-response is sound. The specific numbers should be treated as approximations, not precision instruments.
This is where things get more concerning. The benzodiazepine receptor occupancy data in this book traces back to a single foundational study: Brouillet et al. (1991), which examined benzodiazepine receptor ligands using PET imaging in non-human primates - monkeys, not humans. We are not baboons. This study is referenced extensively throughout the benzo chapter - I found it cited on over 20 pages.
The diazepam receptor occupancy curve - which the book then uses as the template for ALL benzodiazepines via equivalency tables - is derived from monkey studies, not human clinical data. The book applies this single primate-derived curve to alprazolam, clonazepam, lorazepam, and every other benzodiazepine by using potency conversion tables.
This represents a significant chain of extrapolation: primate GABA-A receptor binding data → diazepam dose-occupancy curve → application to all other benzodiazepines via equivalency ratios → specific step-by-step tapering tables with stated receptor occupancy percentages carried to one decimal place. Each link in this chain adds uncertainty, but the tables present the final numbers with apparent precision.
The book admits in a footnote on page 246 that "for some medications, particularly benzodiazepines and mood stabilizers, we just know less in terms of research about the dose at which tapering typically needs to slow down." Yet it still provides specific receptor occupancy percentages for every benzodiazepine taper step, derived from primate studies and equivalency tables.
Both key Horowitz papers cited in this book explicitly describe their tapering proposals as hypotheses requiring further testing. The 2019 Lancet Psychiatry paper states: "This paper offers a pharmacologically-informed guide to withdraw from SSRIs. Its validity should be confirmed by randomised controlled trials." The 2021 Schizophrenia Bulletin paper on antipsychotics says: "The hypothesis put forward in this paper should be tested in further tapering trials."
No such randomised controlled trials have been completed. Yet the book presents the resulting tapering schedules as clinical guidance - more definitively than the underlying papers warrant.
I found 37 instances of "in preparation" citations across the 587-page book, of which 26 are Horowitz's own unpublished work. These trace back to approximately four or five unique papers that are cited repeatedly throughout different drug sections.
The most significant is "Horowitz M, Taylor D. Withdrawing from benzodiazepines and z-drugs (in preparation)" - which appears as a primary reference in virtually every individual benzodiazepine drug section. As of March 2026, this paper remains unpublished. Yet it serves as a key supporting reference throughout the benzodiazepine chapter.
Another repeatedly cited unpublished work is "Moncrieff J, Read J, Horowitz M. Severity of antidepressant withdrawal effects versus symptoms of underlying conditions (in preparation)." This also remains unpublished.
Citing your own unpublished work in a clinical guidebook is problematic. These references cannot be independently verified by clinicians or patients. They create an appearance of evidence that doesn't yet exist in peer-reviewed form. While self-citation of published work is standard academic practice, self-citation of unpublished work in clinical guidance is a different matter - particularly when that guidance will directly influence how patients' medications are managed.
I searched for both key "in preparation" papers referenced in the book: the benzodiazepine tapering paper and the Moncrieff withdrawal severity paper. Neither appears to have been published in a peer-reviewed journal as of March 2026 - over two years after the book's publication.
The following gaps were not covered in my original YouTube video review. They emerged from the deeper analysis I conducted while writing this expanded review - reading the full 587 pages cover to cover, searching for specific terms, and cross-referencing with other withdrawal literature including Anders Sørensen's Crossing Zero. These are significant omissions that clinicians and patients should be aware of.
The terms "MCAS," "mast cell," and "histamine intolerance" do not appear anywhere in this book. Zero mentions across 587 pages.
This is a significant gap because mast cell activation and histamine reactions are widely reported in the withdrawal community. Many people going through benzodiazepine or antidepressant withdrawal develop new sensitivities to foods, chemicals, supplements, and even excipients in their own medications. The book describes this phenomenon indirectly - it discusses how patients can become "sensitised to a range of medications" during withdrawal, quoting Professor Ashton: "Presumably the general hypersensitivity of the nervous system magnifies the reaction to any foreign substances, but no clear explanation has yet emerged." But it never names the likely mechanism or provides guidance on managing it.
Agomelatine (Valdoxan) is included in the book with a full tapering section (pages 159–162), despite being classified as the lowest withdrawal risk antidepressant and despite the book's own acknowledgement that "no withdrawal effects were demonstrated" in formal studies (only "informal reports"). Given its extremely short half-life (1–2 hours) and completely different receptor mechanism - melatonin MT1/MT2 agonism rather than serotonin transporter action - the question is whether it belongs in a deprescribing guide at all.
I have personal experience with agomelatine. When I came off it, my doctor said I could stop cold turkey because it doesn't cause dependency. Whether what followed was withdrawal or simply relapse is debatable. But here's an interesting thought: agomelatine's melatonin agonism makes it a powerful sleep aid, and the first night I ever took it I slept eight hours straight - something that essentially never happened in my adult life. Given that insomnia is one of the most devastating symptoms during psychiatric drug withdrawal, agomelatine might actually have a role as a supportive medication during tapers - not something to deprescribe, but something that could help people sleep while coming off other drugs. The book doesn't explore this possibility.
While the book does discuss CYP enzyme metabolism for several antidepressants (P450 2D6 for paroxetine and fluoxetine, P450 1A2 for fluvoxamine, P450 3A4 for norfluoxetine), it completely omits CYP2C19 - the primary enzyme responsible for diazepam metabolism.
This matters because the book presents diazepam as the preferred benzodiazepine for tapering due to its long half-life. But approximately 15–20% of certain populations are poor CYP2C19 metabolisers, which means diazepam will behave very differently in these individuals. There is no mention of this, no suggestion of pharmacogenomic testing, and no discussion of what to do if diazepam doesn't suit a patient's metabolism.
To borrow a South Park reference - that's essentially the book's position on supplements. The benzodiazepine chapter's only real mention of supplements is extremely brief (roughly half a page), essentially stating that "there has been almost no formal research" and then grouping CBD oil with phenibut and valerian as "particularly unwise" to take during withdrawal.
This is a serious failure of nuance. Phenibut is a GABAergic drug with real dependency potential - grouping it alongside CBD (which has a strong safety profile and emerging evidence for anxiety) is like grouping heroin with ibuprofen because they both affect pain. CBD has been specifically studied in anxiety contexts. Dismissing it in a single sentence alongside an addictive substance does patients a disservice. When I raised this directly with Mark Horowitz in email exchanges in 2023, the response I got was not particularly illuminating.
Magnesium is perhaps the most glaring omission. The word doesn't appear in this 587-page book. Not once. Magnesium glycinate specifically is one of the most commonly used supplements in the benzo withdrawal community - it's involved in hundreds of enzymatic processes, plays a role in GABA receptor function, and many people in withdrawal are depleted. Multiple people I've worked with, including well-known figures in the benzo community, have used it throughout their tapers with benefit. Of course, there's a caveat: during withdrawal, people can be sensitised to everything, and starting magnesium at too high a dose can cause reactions - just like feeding a starving person a complex meal can be dangerous. You start low and go slow. But the book doesn't discuss any of this.
Omega-3 fatty acids, B vitamins (where different forms matter - some cause reactions in benzo withdrawal while others don't), and vitamin D are similarly absent from any meaningful discussion.
People in withdrawal frequently develop severe reactions to inactive ingredients in their medications - dyes like tartrazine (Yellow #5), fillers, binders, and coatings. Switching between generic manufacturers with different excipients can destabilise a taper. The book doesn't mention tartrazine, doesn't discuss excipient sensitivity, and doesn't warn about the dangers of pharmacy-level generic substitutions during a taper. This is practical, life-affecting information that any clinician managing a taper needs to know.
These are two of the most widely recognised phenomena in the withdrawal community. "Windows and waves" describes the characteristic pattern of withdrawal where periods of relative wellness (windows) alternate with periods of increased symptoms (waves) during recovery. "Interdose withdrawal" describes breakthrough withdrawal symptoms between scheduled doses of short-acting medications. Neither term appears in the book.
Reinstatement - going back onto a medication after withdrawal symptoms become unmanageable - is one of the most critical and anxiety-inducing decisions a tapering patient faces. The book's coverage is very brief, appearing primarily on page 378 in a short passage discussing "test re-instatement" and noting that patients "may need titration to approximately the same dose on which they were previously stable." There is no dedicated section, no guidance on timing, no discussion of partial reinstatement, and no acknowledgement of the significant community knowledge that exists on this topic.
The book provides no crisis protocols for severe withdrawal reactions - akathisia emergencies, severe insomnia crises, or acute destabilisation. While akathisia is mentioned 31 times in the book, there is no dedicated section on emergency management of withdrawal-related akathisia, which can be life-threatening.
The book contains important disclaimers that deserve attention. On page 15, it states: "We do not claim that this advice is necessarily 'correct' or that it deserves greater prominence than the guidance provided by other professional bodies or special interest groups." It also states: "No liability is accepted for any injury, loss or damage, however caused."
These are unusually frank disclaimers for a clinical guidebook bearing the Maudsley name. They're also honest - which I respect. But they also mean that if a patient follows the tapering tables and has a bad outcome, the authors have pre-emptively disclaimed responsibility. This creates an uncomfortable tension: the book carries the authority of the Maudsley brand and presents specific numerical guidance, while simultaneously disclaiming that any of it is necessarily correct.
David Taylor has received research funding and speaking honoraria from Lundbeck and Servier - both antidepressant manufacturers. This is disclosed and doesn't invalidate the work, but readers should be aware.
I want to be transparent about my personal history with the author, because it's relevant to both this review and to the broader question of how researchers in this field engage with the patient community.
I first contacted Mark Horowitz in June 2023, while I was in severe benzodiazepine withdrawal. I'd seen his Benzo Warriors lecture and was impressed. I had already created my own exponential tapering spreadsheet - freely available, used by people across multiple benzo communities - and I had one specific question: how to handle the long tail at the end of an exponential taper, where the mathematics means you spend a disproportionate amount of time on the final few percent.
Mark's first response was to offer me a paid academic consultancy session at AUD$250 per hour. I was unable to work due to my withdrawal condition and told him I couldn't afford this. I just needed the answer to one question. His response, in email, was to suggest that if I encouraged "some of the better off people to buy a copy of the book," his publisher might be "more well bestowed" to me - implying that if people with money bought his upcoming book, maybe I'd get access to the tapering data I needed.
The irony of this, which I couldn't have known at the time, is that the tables I was hoping to gain access to turned out to be built around pill fractions rather than consistent mathematics. The very "tail" I was asking about - the final portion of the taper that even Anders Sørensen, who worked directly with Mark, identifies as the most critical part - is where the book's tables are at their most problematic, with receptor occupancy jumps that violate the book's own stated limits.
To his credit, Mark eventually did share a chapter and explain the theoretical difference between exponential and hyperbolic tapering. He was polite and his explanations were technically sound. But when I asked specific practical questions - particularly about why he dismissed CBD as a tapering aid in a lecture I attended, describing it as essentially swapping one drug for another - he either gave non-answers or simply stopped responding. Multiple follow-up emails went unanswered for weeks or months.
When I finished my taper in late 2024 and told him I was planning a video review - offering to share the errors I'd found and inviting his response - he replied that he'd be "happy to know about any errors." When I asked whether I could reference our previous exchanges, which I considered professional correspondence about a published academic work, he replied that he would prefer the conversation not be aired publicly. I have published my email exchanges with him in a separate video.
I want to be fair here. Mark Horowitz is clearly passionate about this subject. He told me he'd made "a few cents an hour" for the work he'd done and that his primary concern was getting the book on doctors' desks to stop the prescribing disaster. I believe that's sincere. But I also believe that when a person in severe withdrawal - confused, scared, unable to work - reaches out to the leading researcher in the field with a single practical question, the response shouldn't be a paywall or a suggestion to drum up book sales. There is a disconnect between writing a book about the suffering caused by psychiatric medication withdrawal and then being inaccessible to the people actually going through it.
As of March 2026 - over a year since I sent him my video review and well over two years since our original exchange - Mark has not responded to any of the specific criticisms I've raised about the book. Not the table errors. Not the primate-derived RO curves. Not the unpublished references. Not the CBD question. Silence. I don't know why. Perhaps he's too busy - he's clearly in high demand. Perhaps he disagrees with my analysis but doesn't consider it worth engaging with because I'm not an academic. Perhaps he knows some of the criticisms have merit and doesn't want to publicly acknowledge flaws in a published clinical guideline. Perhaps it's simply easier not to engage. I won't pretend to know what's in his mind.
What I will say is that this pattern - of not engaging with substantive criticism from the patient community - is unfortunately common in this field. It mirrors the very dynamic that created the prescribing crisis in the first place: experts who know best, patients who should comply, and a professional culture where admitting error is treated as weakness rather than scientific integrity. The irony is not lost on me that the book itself eloquently describes how prescriber arrogance and dismissiveness caused untold suffering to millions of people - and yet the same reluctance to engage with uncomfortable feedback from patients seems to persist, even among the researchers who are supposedly on our side. I hope I'm wrong about this. I would genuinely welcome a response.
Before continuing, it's worth understanding where my review sits in the broader landscape of published criticism. The short answer: there isn't any. I searched extensively for every published review, journal response, and community discussion of this book. What I found is remarkable - and alarming.
Nathan Hodson, BJPsych Bulletin (published online 30 Sep 2024; issue Apr 2025) - Nathan Hodson (Warwick Medical School; also affiliated with the University of Southern California) wrote the only formal academic book review I could locate. He describes the tapering tables and receptor occupancy graphs as "one of the greatest strengths of this text." He identifies two valid limitations: antipsychotics and mood stabilisers are absent, and the book explains how to deprescribe but lacks guidance on when. He does not examine whether the tables are internally consistent, does not check the RO calculations, does not note the unpublished self-citations. It's a generous overview, not a technical audit.
Dr Sian Gordon, British Journal of General Practice (Jul 2024) - A retired GP with over 30 years' experience wrote the primary review in the British Journal of General Practice. She praises the "detailed practical advice and extensively referenced background information" and highlights that many GPs remain unaware of hyperbolic tapering. Her criticisms are practical: no mention of menopause, no guidance on deprescribing in pregnancy, and the acknowledgment that the approach is "time-consuming" and potentially "daunting" for GPs. She also reflects - powerfully - on the medical profession's "reluctance to accept what their patients were telling them about drug effects." No examination of the tables.
Marion Brown, BJGP letter (30 Aug 2024; collection Sep 2024) - A retired patient advocate who contributed to the Scottish Parliament petition on prescribed drug dependence. Her response is warm and grateful, defending the book's length and repetitive structure as purposeful ("the essential important deprescribing principles are not overlooked 'in haste'"). She notes that patients are "finding the information within the book invaluable and have been giving copies to their own GPs." This is advocacy, not critical analysis.
Dr Judith Neaves, BJGP eLetter (2 Sep 2024) - An NHS GP educator who is the closest thing to a critical voice in the published literature. She raised concerns about the book's length, price, and practicality for busy GPs, suggesting that a summary might be more useful. Marion Brown's response was that "a summary for GPs is not appropriate" and "there really are no shortcuts." This is the only published exchange that questions the book's utility - and it's about usability, not accuracy.
Benzodiazepine Information Coalition (BIC) — BIC promoted the Maudsley book with a discount code and encouraged readers who found it beneficial to leave a positive Amazon review. That may be intended as advocacy, but it is also a form of review‑steering. I’m not labouring this as a personal grievance — I’m mentioning it because the Maudsley book itself cites BIC as a tapering resource, meaning this isn’t “some random blog on the internet,” it is part of the book’s reference ecosystem.
In a perfect world, a mainstream clinical handbook would stand on primary literature, pharmacopoeia data, and clearly explained methods. In the real world, this book also cites patient‑advocacy resources. That can be a good thing — lived‑experience communities have forced the medical system to take withdrawal seriously — but it also means credibility matters. When an organisation is simultaneously (a) positioned as an authority, (b) fundraising, and (c) actively campaigning for positive consumer reviews, it muddies the signal. The cleaner ask would be: “If you’ve read it, leave an honest review.”
(Personal note, kept brief: when I attempted to raise substantive critiques with BIC and shared a long-form video explaining my concerns, a representative (“Logan”) replied that the volunteer team likely wouldn’t have time to watch it and asked to keep discussion tightly “evidence‑based.” I experienced that as dismissive; you may read it differently. I’m not making this the focus of the review — it’s simply consistent with the broader “promotion first, critique later” posture.)
As of March 4, 2026, TaperClinic’s own published FAQ states that its Drug Tapering Program costs $30,000–$35,000 and its Concierge Program starts at $60,000 per year (source). That is a staggering price point for a population that is often financially depleted by years of iatrogenic harm. Also worth noting (because it speaks to basic “trust signals”): on March 4, 2026 the TaperClinic homepage contained an unrelated paragraph in Spanish promoting Cialis with an outbound link. That kind of website hygiene issue is not what you expect from a medical service selling high‑ticket care.
I also recorded a walkthrough of TaperClinic’s previous website/webinar (before the recent redesign) because the presentation style concerned me. In that video I describe what I saw as a high‑pressure funnel: a long, non‑skippable sales‑webinar format, sweeping assurances about tapering with minimal disruption, and key eligibility/disclaimer details appearing late. If you want to see that older walkthrough: https://www.youtube.com/watch?v=Zuu0ni_eYf8
I’m not alleging criminality. I’m pointing out optics and incentives. From the outside, it can feel like a tight‑knit ecosystem where advocacy, authorship, and paid “expert” services mutually amplify one another. I may be wrong — and I genuinely hope I am — but when authority and money intersect, transparency and methodological clarity matter even more. When an advocacy nonprofit urges its audience to leave positive Amazon reviews (example), and the book itself then cites that nonprofit as a key tapering resource, and that same ecosystem prominently features a $30k–$60k private clinic run by one of its listed advisors — you get a closed loop of credibility. In a crisis community, this can function like a funnel: trust → endorsement → perceived scarcity → high-ticket offer.
One more red flag, because it speaks to basic professionalism: at the time I wrote this section, the public TaperClinic homepage contained an unrelated promotional paragraph in Spanish about buying Cialis with an outbound link. That may be a hacked ad injection or a site hygiene issue — either way, it’s not reassuring when you’re asking people to pay tens of thousands of dollars for medical care (homepage).
On Goodreads (numbers change over time), the book shows a small but highly positive set of reader ratings (for example, around 23 ratings and a ~4.8/5 average when I checked in March 2026). The reviews are mostly from patients and community members, universally grateful. One reviewer noted she "did not read this cover to cover" but bought a copy for her GP. Another, a decade-long withdrawal group founder, called it "an enormous stepping stone." Not a single reviewer, however, appears to be checking the tables, the references, or the math. Amazon features endorsement blurbs from figures like Professor Wendy Burn, Past President of the Royal College of Psychiatrists - standard and expected for a Maudsley series publication.
This is where it gets concerning. The RACGP (Royal Australian College of General Practitioners) has accepted the book as an “Accepted Clinical Resource”. In Australia, the RACGP has endorsed it as an accepted clinical resource, and NSW bodies have produced implementation materials. In the UK, it’s been listed on the NHS Wales e-Library for Health. This means GPs across Australia and the UK are being directed to follow the book's tapering tables - the same tables whose RO drops I've shown range from 2.1% to 5.1% between steps (a 2.4x variation) in clonazepam alone, built around pill fractions rather than consistent pharmacological mathematics, and derived from primate studies that have never been validated in humans.
So here is the situation as of March 2026. Every published review - from psychiatry journals to GP journals to patient advocacy groups - takes the tables at face value. Hodson calls them "one of the greatest strengths." Gordon praises the "detailed practical advice." Goodreads reviewers are grateful the book exists. Nobody has verified the RO calculations. Nobody has flagged the 37 unpublished self-citations. Nobody has examined the AM/PM dose asymmetries or the sawtooth pattern created by forcing a hyperbolic curve through pill-fraction constraints. Nobody has noticed that the term "jump dose" - arguably the most important practical concept for anyone actually tapering - doesn't appear in 587 pages.
I am, as far as I can find, the only person who has actually checked the book's math. I'm a computer scientist, not a doctor. I have a Bachelor's in Computer Science with a Mathematics minor, and I've spent over a decade as a senior business intelligence analyst. I have lived experience tapering off clonazepam. I built a freely available tapering tool that hundreds of people use. And when I checked the numbers that five academic reviewers, multiple health departments, and the Royal Australian College of General Practitioners accepted without verification - I found them wanting.
This is not a gap between "positive academic reviews" and a "negative patient review." This is a gap between people who read the book and people who checked it. The fact that health departments are adopting clinical guidance based on reviews that never examined the core technical content is, to put it as gently as I can, a failure of the peer review process that patients will pay for.
The term "jump dose" — the community term for the dose at which you stop taking the drug entirely — does not appear anywhere in the book’s 587 pages. Yet it’s one of the most important practical questions for anyone tapering: at what dose is it safe to stop?
To be fair, the book does address the concept. It repeatedly states that the final dose before stopping must be “very small” so the last step to zero is not larger (in receptor‑occupancy terms) than previous reductions. It even gives explicit examples in the diazepam section that the final dose may be 1mg, 0.5mg, 0.2mg or lower before stopping, and some taper tables do push down into very small numbers (for example, clonazepam schedules that end around 0.01–0.03mg total daily dose). So the “end‑dose” idea is implicitly there.
But what’s still missing is a clear, patient‑facing translation of that concept into action: how to choose an end point, how to judge readiness, what to expect after stopping, and (crucially) how to practically make the very small end doses if you’re limited to tablets. Some example regimens still end with a big final step (for example, a fast diazepam schedule that goes 2mg → 1mg → 0mg (and in some other benzo tables, 1mg → 0.5mg is one of the last steps)), and the book’s recurring “just add intermediate steps” advice doesn’t come with a worked, step‑by‑step method for producing those intermediates unless you already have liquids, compounding, or precision weighing in place. Mark discusses the end‑point logic more clearly in private emails than the published handbook does. For a clinical manual, this remains a meaningful gap.
The book calls its tapering approach "hyperbolic tapering." I now understand why - the dose-response curve genuinely is hyperbolic, described by the Michaelis-Menten equation, and the tapering approach is designed to produce linear reductions along that hyperbolic curve. So the pharmacologists aren't wrong about the science. But I still believe the term misleads patients.
The actual tapering schedule is not hyperbolic - it's exponential decay. When you reduce by a percentage of your current dose each step, you're following an exponential decay curve. There are two different mathematical functions at work: the hyperbolic curve describes what's happening at your receptors; the exponential decay schedule is designed to "straighten out" that curve so your brain experiences steady, predictable reductions.
When patients hear "hyperbolic tapering" they often think they're following some complex scientific curve, when really they're doing "reduce by X% of your current dose." That's exponential decay. I still believe we should call this what it is: exponential decay tapering, or more simply, percentage-based tapering. Clear language saves lives in this context - when someone is cognitively impaired from withdrawal, "take 10% less than your current dose" is vastly more actionable than "follow the hyperbolic taper."
And here's the deeper issue: nobody - not the Maudsley, not any practitioner - is doing true receptor-occupancy-guided tapering. That would require knowing each individual's EC50 value, which varies by genetics, duration of use, age, and other factors. The published EC50 values come from healthy short-term volunteers. The percentage method works as a practical approximation because it naturally slows down at lower doses without requiring inaccessible pharmacological data.
This book is an important step forward. It represents a mainstream, institutionally-backed acknowledgement that psychiatric drug withdrawal is real, can be severe, and requires careful management. For that alone, Horowitz and Taylor deserve recognition.
But it is not the complete guide that people in withdrawal need. The tapering tables are approximations presented with false precision. The benzodiazepine science rests on primate studies extrapolated through equivalency tables. Critical practical topics are absent or barely addressed - the supplement discussion dismisses CBD alongside addictive substances, MCAS and mast cell reactions go unmentioned, and there’s no emergency protocol for when things go wrong.
Read it for the principles. Understand why gradual hyperbolic reduction matters. But don't follow the tables blindly. Use a proper calculation tool that gives you true percentage-based reductions - like the one I developed, or any tool that lets you control your own taper with consistent exponential decay mathematics. Supplement the book with lived-experience community knowledge - carefully, because community wisdom has its own problems. Learn about MCAS and mast cell reactions. Understand drug interactions and excipient sensitivities. Create an emergency plan. Start any supplements low and slow.
And work with a clinician who has walked patients through the worst of it. Or better yet - a good tapering coach working hand in hand with a flexible prescriber.
People's lives are at stake. If you found this helpful, share it. If you're struggling, reach out. You don't have to do this alone.
And if you're a clinician reading this - listen to your patients. They know their bodies. When they tell you something is wrong, believe them.
In July 2025, Anders Sørensen - a Danish clinical psychologist with a PhD in psychiatry - published Crossing Zero: The Art and Science of Coming Off - and Staying off - Psychiatric Drugs. At 413 pages, it covers all psychiatric drugs: antidepressants, antipsychotics, mood stabilisers, stimulants, and sedatives. The Maudsley Guidelines, by contrast, covers only antidepressants, benzodiazepines, gabapentinoids, and z-drugs. Notably, Sørensen and Horowitz/Taylor have sat on overlapping research teams (Sørensen is a co-author on Horowitz/Taylor-led work), which makes the differences between the two books even more instructive.
Both books place receptor occupancy at the centre of their tapering methodology. Both explain the non-linear relationship between dose and brain effect, both argue that dose reductions must become progressively smaller as the dose decreases, and both use the term "hyperbolic tapering." Both acknowledge that the final milligrams are the hardest part of any taper. Both take withdrawal seriously and treat it as a legitimate medical phenomenon rather than patient anxiety or relapse.
A note on overlap. Crossing Zero doesn’t just “mention Horowitz in passing” — the author explicitly describes collaborating with Horowitz, Framer, Hengartner and Taylor in a withdrawal research group, and the book cites Horowitz & Taylor’s 2019 Lancet Psychiatry paper on tapering. That overlap is not inherently bad, but it explains why parts of the framing feel like the same intellectual lineage. Importantly, the diazepam “examples from practice” in Crossing Zero are presented as illustrative step lists rather than as a schedule derived from any one Horowitz paper — so I wouldn’t treat them as an independent validation of Maudsley’s diazepam maths, nor as obviously dependent on it either.
Tables vs Principles. The Maudsley approach is to provide detailed tapering tables for each drug — specific doses, specific steps, often constrained by pill fractions. This has the advantage of being immediately actionable for clinicians who want “a schedule to follow.” The downside (as I’ve documented throughout this review) is that those tables can smuggle in irregular dose mathematics: inconsistent percentage drops and abrupt transitions that violate the book’s own stated goals.
Endgame and reversibility. This is where the contrast is almost ironic. Sørensen repeatedly emphasizes that the last part of a taper often requires tiny steps — and that if you overshoot and trigger severe symptoms, it can be necessary to go back to the previous dose and then taper more slowly (he explicitly describes reinstating the previous dose promptly in severe akathisia and then tapering more slowly). The Maudsley also acknowledges (in principle) that the final dose before stopping may need to be extremely low, and it gives ranges like 1mg, 0.5mg, 0.2mg or lower for diazepam. But some of its own example regimens still land you at a “big last step” (for example, a fast diazepam schedule that goes 2mg → 1mg → 0mg (and in some other benzo tables, 1mg → 0.5mg is one of the last steps)), and the book’s recurring advice — “add intermediate steps halfway between the doses listed” — is not paired with a practical, reproducible method for calculating and producing those in‑between doses unless you already know how to do liquids, compounding, or precision weighing.
Examples vs executable math. Crossing Zero includes taper examples, but many read like illustrative sequences (a handful of steps moving from one whole‑number dose to another) without explicitly spelling out the percentage drop at each step — rather than a fully calculated, percentage‑driven plan you can follow step‑by‑step to the finish line. The Maudsley gives more drug-specific tables, but those tables still can’t adapt to your pace unless you start doing math (or introduce tools that can). In other words: both books teach principles — neither one reliably gives the “plug in your dose, output a personalised plan, adjust as you go” experience that many buyers assume they’re purchasing.
Where tools like GTT come in. This is exactly why I built GTT: to remove the “table vs guesswork” problem entirely. You don’t follow pre‑determined tables. You choose your own reduction rate, your own hold length, and you can slow down, speed up, or pause based on symptoms — with consistent percentage mathematics under the hood and a clear audit trail of what you actually did.
Crossing Zero takes the opposite approach up front: it teaches the principle of reducing by a percentage of the current dose (often framed as ~3%–10%), then adjusting based on how you feel. That’s conceptually cleaner. But it’s worth noting that the book still includes a long appendix of real‑world “tapering examples from practice” — including diazepam — which are basically step lists plus a rough “~x% steps” label, and it explicitly notes that “microtapering [is] not shown” because it is “highly individual.” In other words: it avoids formal tables, but it doesn’t magically solve the math execution problem for you either. You still need a calculator (or a system) to turn principles into precise, repeatable doses.
Milligram Scales. This is perhaps the starkest practical difference. Sørensen presents a milligram jeweller’s scale as a central, universal tool: weigh the tablet (or beads), remove a tiny amount, and re‑weigh until you hit the target percentage reduction. The Maudsley Guidelines acknowledge jeweller’s scales in the antidepressant bead‑counting discussion, but they do not really present the scale as a default tool for tablet‑based benzodiazepine tapers — leaning instead on tablet fractions, commercial liquids (when available), or extemporaneous suspensions.
This is also where my own position is blunt: for most people tapering tablets, a dry taper with a scale is the most practical way to get consistent percentage reductions without relying on compounding pharmacies or shaky suspensions. I’ve made a step‑by‑step video showing exactly how to do this safely, and how to avoid the common pitfalls: Dry tapering with a milligram scale (my method). I also built a free calculator/tool (GTT) to generate mathematically consistent schedules — not “pre‑determined tables,” but a plan that adapts to your chosen speed and can be adjusted as you go.
Sørensen also covers tapering strips (customised daily-dose packs from a Dutch compounding pharmacy). The Maudsley does discuss tapering strips in its antidepressant chapter, but the option is far less developed outside that context and not treated as a mainstream pathway for benzodiazepine tapers.
Windows and Waves. Crossing Zero dedicates space to explaining the windows-and-waves pattern — periods of relative wellness alternating with symptom flares during recovery. The Maudsley Guidelines don’t use that framing. It does, however, explicitly discuss interdose withdrawal (and tolerance withdrawal) as a real clinical phenomenon, especially with short-acting benzodiazepines. For patients actually going through withdrawal, having both the pharmacological explanation and the lived-experience pattern language can be hugely stabilising.
Reinstatement and Kindling. Crossing Zero provides a detailed discussion of reinstatement - including the concept of a "window of reinstatement" after which the nervous system may no longer accept the medication, and the phenomenon of neurological kindling where repeated starts and stops can make the nervous system hypersensitive. The Maudsley's coverage is a brief passage on page 378. For a clinical manual, the Maudsley's limited treatment of what may be the most high-stakes decision in the entire tapering process is a significant gap.
Scope. Crossing Zero covers antipsychotics, mood stabilisers, and stimulants - drug classes the Maudsley explicitly excludes. This means clinicians dealing with patients on quetiapine, olanzapine, lithium, or methylphenidate will find nothing in the Maudsley but can turn to Sørensen's book. Several published reviewers of the Maudsley, including Nathan Hodson, flagged this omission.
Psychological Dimensions. The entire third part of Crossing Zero - roughly 120 pages - is devoted to life beyond medication: psychological dependence, reconnecting with your emotional self, managing without drugs, the role of social support networks, and even a section on psychosis. The Maudsley is almost entirely pharmacological. For patients whose tapering journey is as much psychological as pharmacological, this is a meaningful difference.
Evidence Base. Crossing Zero draws heavily on dose–occupancy research (including work Sørensen co-authored on antidepressant dose versus transporter occupancy). Unlike the Maudsley book’s frequent use of citations marked “in preparation”, I could not find any “in preparation” citations in Crossing Zero when searching the PDF. The Maudsley’s reliance on a 1991 non-human primate PET study (Brouillet et al.) for benzodiazepine receptor-occupancy curves is also a unique vulnerability.
Neither book mentions MCAS or mast cell activation by name - a gap shared by both. Neither discusses magnesium. Neither provides emergency protocols for severe withdrawal reactions like akathisia crises. These remain topics where the patient community's knowledge significantly outpaces the published literature.
Crossing Zero does mention excipients (fillers, binders, coatings) briefly in its weighing method section, but doesn't address excipient sensitivities, dye reactions, or the danger of manufacturer switches during a taper. The Maudsley does mention excipients/fillers and binders in its discussion of suspensions and dispersing tablets, but it still doesn’t meaningfully address excipient sensitivity, dye reactions, or the real-world instability caused by manufacturer switches during a taper.
Both. They complement each other. The Maudsley gives clinicians institutional backing and drug-specific tables (with the caveats I've documented). Crossing Zero gives patients and clinicians a deeper understanding of the principles, better practical tools, broader drug coverage, and guidance on the psychological dimensions of withdrawal that the Maudsley completely ignores. If you can only read one, and you're a patient tapering off a benzodiazepine or antidepressant, Crossing Zero will serve you better as a companion guide. If you're a GP who needs something to hand to a colleague to prove that hyperbolic tapering isn't fringe science, the Maudsley's institutional weight makes it the more persuasive reference.
Ideally, read both — and then use a proper calculation tool for the actual maths. That’s exactly why I built GTT: it removes the entire ‘pre‑determined table’ problem by letting you set your reduction rate (cut‑and‑hold or daily micro‑reductions), recalculate from the current dose each step, and adjust the plan whenever life or symptoms demand it.
The Maudsley Deprescribing Guidelines is, in many ways, the most important book published in psychiatry in the last decade. Not because it's perfect - it isn't. But because it exists at all. For the first time, a mainstream clinical publisher under one of the most respected names in psychiatric pharmacology has produced a comprehensive guide that says: withdrawal is real, it can be devastating, and here's how to do better.
But I need to say something that's been building throughout this entire review. It makes me deeply frustrated that this is where the bar sits. That a book with primate-derived receptor curves, 37 unpublished self-citations, tapering tables that violate their own stated limits, and a disclaimer saying "this advice is not necessarily correct" - is rightly celebrated as a breakthrough. Because it is one. Anything is better than "just cut in half and stop," which is what most doctors still tell people.
But think about what that means. Think about what it says about how people on psychiatric medication are treated by the medical establishment. If a cardiology textbook based its dosing guidance on a 1991 monkey study, cited its own unpublished papers as primary evidence, and shipped with a disclaimer accepting no liability for any injury - it would never have made it past a publisher's desk. If an oncology handbook told cancer patients to cut their chemotherapy tablets into quarters using a kitchen knife and eyeball the dose, there would be lawsuits. If a diabetes guide had no section on diet, no mention of liver function, and dismissed insulin management tools as "particularly unwise" - it would be retracted.
But this is psychiatry. And these are psychiatric patients. The forgotten ones. The stigmatised ones. The ones whose suffering is routinely dismissed as anxiety, relapse, or attention-seeking. The ones outside the walls of "real" medicine, where evidence standards are higher, accountability exists, and patients are treated as people whose bodies deserve precision. I sometimes think psychiatric patients are treated like medicine's underclass - people who can be mistreated with minimal consequence because they're already marginalised, already disbelieved, already carrying a label that undermines everything they say.
I could be wrong about how other fields compare. Maybe cardiology and oncology have their own blind spots and their own neglected patients. But I know this: the people going through psychiatric drug withdrawal deserve the same standard of evidence, the same precision, and the same accountability that we'd demand for any other medical condition. And right now, they're not getting it.
The fact that I can criticise this book's tables, its evidence base, and its gaps is itself a sign of progress. We've moved from "withdrawal doesn't exist" to "here's a 587-page book on how to manage it, and people in the community are fact-checking the receptor occupancy calculations." That's real. But let's not confuse progress with adequacy.
Use this book as a starting point. Question it. Supplement it. Verify it. Demand better from the next edition. That's what good science demands - and that's what these patients deserve.
Take care of yourselves.
- Guy the Taperman